Raxibacumab
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Raxibacumab: From Inhalational Anthrax to Postinfectious Vasculitis
One-Sentence Summary
Raxibacumab is a monoclonal antibody originally developed to neutralize Bacillus anthracis protective antigen (PA) for the treatment and post-exposure prophylaxis of inhalational anthrax. TxGNN’s top-ranked prediction suggests possible efficacy in postinfectious vasculitis, but this signal is supported by zero clinical trials and zero publications, and the model’s own rationale states no known mechanistic link exists — this is a graph-based (L5) prediction only, and the recommendation is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in Taiwan regulatory data (drug is not marketed locally); publicly known original indication is inhalational anthrax (treatment and post-exposure prophylaxis) |
| Predicted New Indication | Postinfectious Vasculitis |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available as a structured field, but the evidence pack’s rationale confirms raxibacumab acts as a monoclonal antibody that binds and neutralizes the protective antigen (PA) component of B. anthracis toxin — a highly pathogen-specific mechanism with no known role in general immune-complex-mediated vasculitis.
Postinfectious vasculitis is a systemic immune-complex process that can follow a wide range of infections, but it is not driven by anthrax toxin or PA. The repurposing rationale explicitly states: “與感染後血管炎（免疫複合物介導之全身性血管炎）無已知機轉關聯。TxGNN 高分屬圖譜共現訊號，無生物學基礎支持” — i.e., the model’s high score reflects knowledge-graph co-occurrence patterns rather than any established or plausible biological mechanism.
Important context on the broader prediction set: All eight ranked predictions in this evidence pack were reviewed. Ranks 1, 2, 4, 5, 6, 7, and 8 (postinfectious vasculitis, post-infectious syndrome, infective urethral stricture, otitis externa, Chagas cardiomyopathy, infection-related HUS, drug-induced osteoporosis) each explicitly lack mechanistic plausibility per their own rationale text, and none have any clinical trial or literature evidence — all are scored L5/Hold. Rank 3 (“post-bacterial disorder”) is the only entry with strong evidence (L1, 3 clinical trials), but its own rationale flags that this is a semantic restatement of the original anthrax indication, not a genuine new indication — the trials listed (NCT02339155, NCT07478471, NCT02177721) all concern anthrax treatment/prophylaxis directly. It should therefore be treated as confirmation of the known label, not a repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Raxibacumab currently has no license/authorization records in this jurisdiction (total_licenses: 0; market_status: 未上市).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked candidate indication (postinfectious vasculitis) has no clinical trial or literature support, and the model’s own mechanistic rationale confirms no biological basis for the association — this reflects knowledge-graph noise rather than a credible repurposing signal. The only prediction with substantive evidence (rank 3) is mechanistically identical to raxibacumab’s existing anthrax indication and does not represent a novel therapeutic direction.
To proceed, the following is needed:
- Confirmed mechanism-of-action and TFDA label data (currently blocked per data gap DG001/DG002) before any safety evaluation can begin
- A genuine mechanistic hypothesis linking PA-neutralizing antibody activity to a non-anthrax disease process, independent of graph co-occurrence scoring
- If pursued further, reclassify rank 3 (“post-bacterial disorder”) as label-confirmation evidence rather than a new-indication candidate, and exclude ranks 1, 2, 4–8 from further review given L5 status and explicit lack of biological plausibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.